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Abstract
Although clinical trials are rarely of interest to medical sociologists, in the last decades there has been increased focus on the processes of medi-
calization as well on the social critical approach to these multidimensional phenomena by health sociologists. From the perspective of the sociology 
of illness, clinical trials could be perceived as a bridge between the ‘society of remission’ and ‘risk society’. Public opinion polls did not give a clear 
answer regarding the social attitudes and the level of social trust presented by Poles towards clinical trials although patients or healthy volunteers 
are the main subject of this research. Creating an atmosphere of social trust (using the role of mass-media) towards clinical trials (through social 
awareness, methods of investigation and using the results in everyday medical practice) gives a chance to create a new ‘quality of relations’ between 
scientific teams responsible for clinical trials and society.
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Introduction
In the last decades medical sociologists, especially 
health sociologists, have shown unprecedented interest 
in the processes of medicalization in its various dimen-
sions and at different levels of social impact [1–3], as 
evidenced by entire monographs devoted to this com-
plex and multidimensional process [4]. It is an attempt 
to transfer onto Polish soil the theoretical assumptions 
and observations based on reflection and experiences 
on ‘medical imperialism’ in the form of interference of 
medicine in the daily functioning of modern societies. 
Admittedly, Polish medicine has adopted the trend and 
has fully taken on a dictatorial role with regard not only 
to lifestyle, but also to other behaviours. However, in 
the broadly considered issues regarding the processes of 
medicalization, pharmaceuticalization and biotechnology 
of social life [5], indicating that medicine took control 
over social life, the issue of clinical research has so far 
not been of special interest to medical sociologists, par-
ticularly in relation to the sociology of illness.
In the article Medicalization – the perspective of the 
usurper, A. Ostrowska affirms that “the doctor’s voice 
should be decisive in many issues where death, suffering, 
quality of life, pain and dying are at stake”, but adds: 
“the created faith in the possibilities and exclusiveness 
of medicine has made the doctor insufficiently respectful 
of patient subjectivity and the principle of partnership in 
mutual relations” [1, p. 43]. The author also points to the 
fact that “certain attributes of professional domination 
Zdrowie Publiczne i Zarządzanie 2018; 16 (1): 26–34
www.ejournals.eu/Zdrowie-Publiczne-i-Zarzadzanie, doi:10.4467/20842627OZ.18.004.8674
Przygotowanie do wydania elektronicznego finansowane w ramach umowy 641/P-
-DUN/2018 ze środków Ministra Nauki i Szkolnictwa Wyższego przeznaczonych na 
działalność upowszechniającą naukę.
27Zdrowie Publiczne i Zarządzanie 2018; 16 (1)
postawy i przekonania laików na temat instytucji 
medycznych oraz ich zdrowotne konsekwencje
are also the result of social pressure and the actions of 
specific pressure groups composed of health care users 
(...). The primary goal of doctors’ activities is treatment, 
and further, improvement of the patient’s quality of life” 
[1, p. 47]. The implementation of these goals is directly 
and indirectly carried out by clinical research. Therefore, 
a question may be raised whether they are a manifesta-
tion of a positive or negative impact of medicalization.
The perspective of the sociology of illness allows 
finding links between the various stages of the social 
process of the illness, which has its beginning (assum-
ing the role of an ill person), a social course connected 
with a certain trajectory, depending on the duration of the 
process and the ability to control its course and the final 
stage, which can mean “approaching recovery” or vice 
versa – the stage of dying, of variable duration [6, 7]. 
According to Giddens [8], illness as a life experience [9], 
includes the process of subjective describing the self-
perspective of illness behaviours, based on interpretation 
and actions undertaken by the patient. In this context also 
clinical trials could be situated.
Regardless of the degree of awareness of the impact 
of medicalization, the relationship between medicine and 
society has always focused on two basic values, i.e. hu-
man life and health; however, in recent decades, these 
interconnected relationships have undergone profound 
transformations and become much more complex, pri-
marily as a result of civilization changes, increase in 
general awareness, technological progress and new scien-
tific discoveries. Social determinants of changes in these 
relations result not only from the impact of civilization 
progress on living standards and general quality of life, 
changes in lifestyles, increase of behaviours that do not 
necessarily treat health as a ‘desirable value’, and persist-
ing social inequalities, consequently leading to inequali-
ties in health status. Deep changes in all dimensions of 
social life (also under the influence of medicalization), 
have significantly influenced the expected scenarios of 
developing “the entire living space”, at the same time 
leading to the emergence of new threats of not only civi-
lization, but also health, nature.
Demographic changes observed in developed coun-
tries, associated with extending the average life expectan-
cy (thanks to controlling a majority of infectious diseas-
es), have had a significant impact on the epidemiological 
changes in the course of diseases (chiefly observed since 
the second half of the twentieth century), and led to new 
challenges faced not only in medicine, but equally in 
social reactions to the process of the medicalization of 
social life. They have become an impulse for adopting 
a new perspective on the fight against chronic diseases, 
which constitute social problems, both in the global di-
mension and in relation to particular societies. The rapid 
aging of societies, the severity of chronic diseases and the 
accompanying disability, have caused a clash of medi-
cine with a new ‘quality of illnesses’ regarding morbidity 
and in the reported causes of mortality. These sometimes 
dramatic transformations have become the basis for new 
challenges facing medicine, but also for new expectations 
of society regarding the broadly understood medicine, 
medical professionals, scientists working in the area of 
basic science, as well as researchers carrying out clinical 
trials bridging the gap between scientific experience and 
introducing the results of these experiences into everyday 
medical practice in the form of new treatment or pharma-
cotherapy.
These expectations resulted from appreciating the 
fact and awareness that there is no possibility of further 
systematic development of medicine without scientific 
research – the position of medicine and society on this 
issue is usually compatible, based on the belief that the 
chances of recovery depend on the treatment methods 
used and in the case of many illnesses, waiting for new 
methods of treatment is tantamount to extending life. Ad-
vances in medicine are an integral part of the progress of 
civilization, including challenges faced by medicine in 
the pursuit of the aetiology of diseases, especially chronic 
ones, changing the definition of ‘incurable’ to ‘curable’, 
expanding knowledge about their effective treatment or 
curing the disease.
Although these expectations are shared by both sides, 
i.e. the world of medicine and society, they have a dif-
ferent perspective on the process of achieving medical 
success and new methods.
What seems obvious to the representatives of medical 
professions and research teams working on new methods 
of treatment is not similarly perceived, evaluated or ap-
preciated by various social groups of recipients, i.e. pa-
tients treated for various reasons.
The basic question – on the one hand – are the meth-
ods of conducting further scientific research on effec-
tive treatment methods, lowering the mortality rate due 
to civilization diseases, and on the other – the impact of 
the process of medicalization (its positive and negative 
dimensions) on the role and importance attributed to 
clinical research in public awareness, in a society that is 
not immune to life-threatening diseases, taking their toll 
in all age groups. Often, the very term ‘clinical trial’ is in-
comprehensible or falsely understood, and accompanied 
by various types of emotions, not always positive.
Also, the messages communicated to the general pub-
lic, i.e. criticism of the process of medicalization, indicat-
ing examples of ‘selling sickness’, is not conducive to 
building a positive attitude towards clinical trials [10]. 
The overwhelming influence of the medicalization pro-
cess on everyday social life has led to the emergence of 
a society dependent on drugs, a drug-dependent society, 
consequently dependent on the products proposed by 
pharmaceutical concerns and the unclear role of clinical 
trials sponsors controlling their results, which raises the 
question of how the published results are objective, fair 
and independent of sponsors [11].
There is a dearth of information that is communi-
cated to society about various aspects of clinical trials, 
in particular about the rules of recruitment for research 
(the more so that often the rules of inclusion or exclusion 
are not understood by lay people, which raises concerns 
and suspicions about the integrity or privileged position 
of the people included in research) and the anticipated 
effects of research in a given field of medicine that are 
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beneficial to people suffering from a specific disease. 
This leads us to the next question – why many clinical 
trials are conducted in certain groups of diseases (e.g. 
cancer, cardiovascular system), and less so in other, and 
therefore, what the premises for undertaking research are 
and how the public should be (in a way that would be 
understandable for them) informed about the scope of 
clinical trials and related costs, both economic and social. 
Public opinion polls on clinical trials show a lack of trust 
in the information provided on clinical trials, indirectly 
confirming distrust of the very idea of these studies, re-
sulting from the fact that knowledge about them is trans-
mitted inadequately [12].
The struggle that the purpose of clinical trials be 
understood is connected with the necessity of overcom-
ing stereotypes and biases against these studies, without 
which medical progress is impossible and without which 
there would be no new therapies. All the same, it is dif-
ficult to refute the view existing in social consciousness, 
namely of patients being used as ‘guinea pigs’. Rebut-
ting this myth should reinforce the belief that without the 
participation of the sick (patients, volunteers) there is no 
possibility to try out new therapeutic methods.
The socio-cultural context should also be taken into 
account, which clashed against the successive stages 
of the medicalization process, both in the dimension of 
positive medicalization and manifestations of negative 
medicalization, criticized from the perspective of various 
social actors.
The impatience caused by failed applications of cer-
tain therapies is associated with expectations of new, 
more effective drugs. Patients often do not take into ac-
count the fact that those drugs that have not passed clini-
cal trials cannot be included in standard therapies or al-
lowed to be sold on the pharmaceutical market.
Social expectations regarding clinical trials 
Clinical trials do not attract special attention in the 
public’s general awareness – even the media’s publicized 
achievements in the form of spectacular discoveries of 
new therapeutic methods, actually changing the state 
of knowledge and medical expertise, are often barely 
noticed as the ‘news of the day’. There is a widespread 
view that clinical trials are not of interest to healthy peo-
ple who want to ‘push away’ the idea of disease and suf-
fering.
Low interest in clinical research taken by healthy peo-
ple is often accompanied by lack of reliable knowledge 
about the purpose of such research, leading to the dis-
semination of many false and negative stereotypes and 
myths, and the emergence of a variety of social attitudes 
towards clinical trials.
The degree of interest in clinical trials is radically 
increased in the face of threats to one’s own health or 
the health of our dearest, especially children. In such 
circumstances, especially in the case of a disease that is 
very difficult to cure or which is considered incurable, 
the interest in new treatment methods grows rapidly, and 
so does hope and anticipation of a new, more effective 
drug, which would give a chance to heal the disease or 
improve the quality of life in a situation of a permanent 
threat to health or life. This faith and hope are associ-
ated with the expectation to change the position of the 
patient, from “being a victim of a given disease, often 
identified with the death sentence” to the position of 
“a person who overcame a disease, who has succeeded, 
who has been successfully cured”, although many times 
success means only delaying the risk of losing one’s life. 
In the case of an incurable disease associated with pain 
and suffering, expectation means the possibility of ob-
taining a more effective drug that would relieve severe 
pain and suffering.
In post-modern society, analyzing the contemporary 
multidimensional association between the social determi-
nants of health status involving a relationship between 
society and the causes of disease or the health risks, clini-
cal trials can be placed on the axis building a bridge be-
tween the so-called ‘remission society’ and ‘risk society’ 
[13]. According to Frank [14], remission society consists 
of an increasing number of people who have undergone 
a specific disease and are now considered cured, which 
does not mean that their health may not deteriorate and 
the disease return, e.g. in the form of cancer. As the term 
itself indicates – ‘remission’ does not entail a guarantee 
of being completely healed, elimination of the recurrence 
of the disease, but for this category of people clinical tri-
als are a chance to counteract or control the recurrence 
of the disease, not allowing relapse. Regarding the other 
end of this axis, we can refer to Beck’s risk society [15], 
in which, along with other known and unknown threats, 
clinical trials may be associated with the risk of introduc-
ing new, not completely tested methods of treatment (e.g. 
in the form a new drug) or be a source of other threats, 
such as using all possible therapeutic methods.
Epidemiological indicators, for example in the form 
of data on mortality due to specific diseases or morbidity 
for various reasons, clearly show groups of patients re-
quiring medical intervention. Therefore, it is worthwhile 
asking whether criticizing the process of medicalization 
by seeing clinical trials as a way of using patients to 
achieve goals related to the functioning of pharmaceuti-
cal companies [11] is always justified, all the more that 
this criticism never refers to life-threatening diseases 
or irretrievable loss of health. It should be emphasized 
that clinical trials concern diseases located in the high-
est hierarchical structure, which results from their clear 
definition in relation to the biomedical model, whereas 
medicalization usually concerns less precise states, e.g. 
regarding mental health [16, 17]. In the absence of effec-
tive methods of controlling certain diseases and treatment 
that would stop the progression of the disease, society 
grows impatient, questions the competence of research 
teams and criticizes the search for new effective thera-
pies as being too long, often taking years, and not always 
successful. Therefore, lack of faith in the effectiveness 
of clinical trial results is reinforced by a general sense 
of deficiency and disappointment with modern medicine, 
related to the fact that it is impossible for medical profes-
sionals to implement the ‘therapeutic scenario’ construct, 
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according to which all patients are effectively treated and 
morbidity and mortality rates are visible reduced.
Poles’ attitude towards clinical trials 
There have been very few studies on Poles’ attitude 
towards clinical trials. The difficulty in assessing the 
value of these studies results from the different method-
ologies used and the different size of the groups in which 
the research was carried out. A small study conducted in 
a group of 100 people over 18 showed a negative attitude 
to clinical trials, also identifying the need to conduct such 
tests. For the majority of respondents, drug testing was 
associated with a threatened sense of security, and almost 
half of the respondents would not recommend a relative 
or a friend to participate in a program of testing new 
drugs [18].
A larger study, i.e. the PBS DGA Report conducted 
in 2010 involving a representative group of Poles, also 
yielded doubtful results, since it was a commissioned 
study, and so the results of the report should be treated 
with caution [19]. The results of the PBS DGA Report 
indicated a great interest of Poles in clinical trials: 2/3 of 
those surveyed heard about clinical trials, i.e. drug test-
ing, and the percentage of people responding positively 
to this question rose with increasing education: 52% of 
people with primary education heard about clinical tri-
als, compared to 71% people with secondary education 
and nearly 89% people with higher education. The least 
willing to participate in clinical trials were elderly people 
(over 59 years of age) who – also less frequently than 
other participants of the study – heard of clinical trials. 
To those who have heard about clinical trials, they were 
associated primarily with medical progress (35%), with 
experiment (30%), with the introduction of new drugs 
(28%), and with a chance to improve patients’ health 
(21%). Other responses included the indication of risk, 
danger for patients (12%), financial benefits for patients 
(6%), unfair activity of pharmaceutical companies, aimed 
at increasing sales of a given drug (5%), financial benefits 
for doctors (4%), deterioration of patients’ health (3%). 
The options presented to the participants regarding the 
potential serious threat to their health (e.g. in the case of 
diabetes) and the choice between the standard treatment 
method and the possibility of participating in a clinical 
trial testing a new, more effective method, have shown 
that the decision to participate in such a clinical trial was 
taken by an average of 60% of respondents, while in the 
situation of the diagnosis of cancer, participation in the 
clinical trial was declared by ¾ respondents of those who 
heard of clinical trials (39% expressed a strong desire to 
participate in the experimental method, while 23% would 
not take such a step) [19].
Commenting on the results of the PBS DGA Report, 
Prof. Z. Szawarski said: “Poles are eager to participate 
in research, because they are primarily driven by their 
own interest”, excluding participation in research due to 
other motives, such as “strictly moral reasons: altruism, 
solidarity, moral duty, religious considerations” [19].
Clinical trials have given rise to many fallacies and 
negative emotions, mainly concerning the rules of par-
ticipation in them, such as the way of recruiting people 
who are ill or healthy, determining the social position of 
beneficiaries of clinical trials (individuals, groups of pa-
Figure 1. Multidimensional model showing the relation between remission society and risk society.
Source: Own study.
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tients of a certain age, education, health status, chances 
of full recovery), social messages accompanying clini-
cal trials, and social and economic costs incurred due to 
these studies. Of particular importance are social costs 
resulting from mistakes committed when introducing 
drugs before they have been fully tested or promoting 
such drugs, illustrated by the example of Thalidomide 
– the infamous drug advertised as an effective means of 
preventing adverse symptoms accompanying pregnancy, 
which should be a warning to all actors involved in 
clinical trials; as a result of using this preparation, about 
10,000 children were born with hypoplasia of upper and 
lower limbs.
Taking into account the years of discussion and seri-
ous consideration of the role of medicalization and phar-
maceuticalization of social life, of negative consequences 
of these processes and taking action towards demedicali-
zation of social life [2] – even the negative consequences 
of unjustified, or even unauthorized medicalization – the 
fact that the fight against modern diseases is not possible 
without clinical trials cannot be obscured. 
Poland belongs to countries with one of the lowest 
rates of clinical trials (currently below 400), as well as 
the lowest number of patients included in these studies 
[19]. Accordingly, do these indicators (contrary to the 
respondents’ declarations from the study cited) point to 
negative social attitudes towards clinical trials, or do they 
result from low public awareness, lack of reliable knowl-
edge about clinical trials, underestimation of their role in 
modern medicine, especially in relation to the situation of 
people who are currently suffering from an illness, par-
ticularly those suffering from diseases that cause loss not 
only of health but also life, or are an expression of wider 
social attitudes, which include loss of trust in doctors, 
medical institutions, pharmaceutical companies, or the 
motive for which research is carried out being assessed as 
low, or undermining the reliability of results, and finally 
the ‘suspicious’ role of sponsors in obtaining results?
Taking into account the variety of conditions deter-
mining social attitudes towards clinical trials, it is dif-
ficult to give an unequivocal answer – most probably the 
increase in public awareness of new medical technologies 
is a desirable factor, just like the expectation of ensuring 
safe use of drugs or therapies, and finally – expectations 
related to personalized medicine [20, 21].
The diverse emotions accompanying clinical trials are 
not only connected with the clinical aspect of these stud-
ies, but are primarily focused on social aspects related 
to social trust as defined by P. Sztompka, who points to 
the significant role of trust in relations with medical in-
stitutions. According to P. Sztompka, “trust becomes the 
basic strategy of dealing with uncertainty and inability to 
control the future (...) trust has a specific addressee and 
its foundation are the expected reactions of others to the 
trust we place in them”. Expressing consent to participate 
in a clinical trial is an act of confidence – “entrusting 
oneself, the most precious values of one’s health or life” 
[22]. Signing consent to participate in a clinical trial, 
submitting oneself to new, often experimental therapy, 
also means “renouncing a part of control over one’s own 
destiny and the decision to become partially vulnerable 
and incapacitated” [22].
Regarding participation in a clinical trial, social ex-
pectations also concern the extent to which its organizers 
meet their obligations towards the participant confiding 
in them to confirm the reliability of research and results, 
demonstrating that the clinical trial is controlled in order 
to monitor its possible negative consequences, and in the 
event of their occurrence, to interrupt testing, ensuring 
the participants’ safety and eliminating any side effects. 
The fact that a participant places their trust in a medical 
institution or a team of researchers carrying out the clini-
cal trial, should oblige them even more to comply with all 
the ethical principles currently required.
The decision related to participating in a clinical trial 
is not immune from risk resulting from the possibility 
of unforeseen adverse effects or lack of expected results 
(health improvement), as well as the failure to fulfil the 
hope associated with the study. The consent to undergo 
therapy involving new drugs or other forms of experi-
mental therapy is always associated with a health risk, 
or possible side effects. These risks may cause the par-
ticipants to decide to withdraw from the study, or the 
research team to decide to discontinue the clinical trial 
after analyzing the benefits and losses (costs) associated 
with it.
The institutionalized risk in the case of clinical tri-
als undertaken by medical institutions is closely related 
to the principles of the functioning of these institutions. 
Public trust in medical institutions conducting clinical tri-
als, as well as pharmaceutical concerns, usually appear-
ing as sponsors of clinical trials, is the result of collective 
or individual experiences [23].
Gałuszka [24], in turn, draws attention to the phar-
maceutical risks associated with the production and dis-
tribution of medicines and the organization of medical 
services as well as risks resulting from medical errors. 
Referring to contemporary bioethics, Gałuszka [24] 
points to four main principles: the principle of autonomy, 
doing good, avoiding evil and of justice.
The role of patients in clinical trials
The messages addressed to the public not only in-
dicate that there would be no new therapies without re-
search, but also strongly emphasize the importance of the 
participation of volunteers or patients since clinical trials 
simply cannot be conducted without their participation. 
Patients taking part in clinical trials validates them, at 
the same time giving the participants the moral right to 
decide in which clinical trials they want to be included 
(patients’ decision), the more so because patient provides 
information about how to assess their quality of life 
during and after the tests; this knowledge enriches the 
knowledge of researchers with valuable data.
Patients’ organizations emphasize the role of patients 
in clinical trials, often pointing to altruism as the reason 
to participate. Showing the significance of the role they 
play – by appreciating the opinion and views of patients, 
and the increasing knowledge about their task – is aimed 
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also at convincing other people to take part in research. 
The importance of involving patients in research devel-
opment (according to the European Patients’ Academy) 
is highlighted.
The group whose participation in clinical trials is 
chiefly discussed are elderly people. On the one hand, 
there is a small number of elderly people taking part in 
clinical trials, which means that they are more likely to 
take medicines that have not been tested for their age 
group or are refused treatment because of the lack of 
data on the effectiveness of certain drugs in the older 
age group [25]. K. Szczerbińska cites the results of a re-
view of clinical trials on the most characteristic diseases 
affecting the elderly (e.g. heart failure, hypertension, 
Alzheimer’s disease, depression, Parkinson’s disease, 
cancer), which clearly prove scarce participation of the 
elderly in these studies. On the other hand, though, re-
search shows that medical workers seldom recruit older 
people for clinical trials, especially when this participa-
tion does not have a clear benefit for the elderly patient. 
In addition, older patients are perceived as reluctant to 
undergo changes in their current treatment, expressing 
fear of experiments, or being an object of experience, 
and refusing to participate in these studies [25]. Research 
aimed at establishing the attitudes of medical workers 
towards including the elderly in clinical trials has shown 
that more than half of Polish medical employees agree 
with the statement that older age should not be an obsta-
cle to inclusion in clinical trials, especially so because 
about 88% of respondents confirm that older people are 
not sufficiently represented in clinical trials. Objective 
obstacles related to the participation of the elderly in 
clinical trials are associated with the frequent occurrence 
of many concomitant diseases in the elderly, taking too 
many medicines, cognitive impairments, more frequent 
adverse events, disability, difficulties in recruiting older 
people for research, and a higher probability of refusing 
to participate in the study, lack of interest of older people 
in clinical trials and a greater probability of the elderly 
not complying with the requirements [26].
Due to communication barriers in reaching the insti-
tution offering participation of elderly people in research 
while guaranteeing their rights and respect for health, the 
Charter of the Rights of the Elderly has aided the efforts 
to increase older people participation in clinical trials. It 
defines the conditions for obtaining informed consent 
for participation in clinical trials, information about the 
purpose of the experiment, the expected benefits and pos-
sible risks, and discomfort that can be experienced by the 
person taking part in the study. The consent to participate 
in the study must be confirmed in writing or with the 
presence of witnesses [27].
Slogans, such as “women in clinical trials – make 
changes for the better – ask your doctor if clinical tri-
als are right for you”, promoted by the FDA Office of 
Women’s Health raise the question whether the incentive 
to participate in clinical trials is an expression of an-
other (unnecessary) interference of medicine in women’s 
health? Do promotional materials containing “facts that 
you should know before you become a participant in 
a clinical trial” serve to manipulate women’s decisions 
by pointing to participation in clinical trials as an inde-
pendent decision? [28].
In summary, information addressed to potential 
participants in clinical trials should indicate the quality 
of clinical trials, their transparency, type of study and 
its subject, the number of patients, research goals, and 
sources of financing. Participants should receive infor-
mation during clinical trials on the doses of medication 
received, be asked about or report positive and negative 
effects (side effects). Also, the final results of clinical tri-
als (data) and the interpretation of the research process 
should be presented to study participants primarily from 
the perspective of their safety.
Communicating test results
The development of new drugs is a long-lasting pro-
cess, and so informing on the complexity of the drug 
development process, the legal and ethical regulations in 
place used to monitor the process and ensure the safety of 
medicines, can enhance confidence in such undertakings 
[29, 30].
Messages addressed to the public concerning clinical 
trials, recipients of this information and especially their 
results, depend on the health literacy [24], which consti-
tutes a significant obstacle in understanding the purpose 
of clinical trials and in relations based on partnership and 
mutual communication between the participant of clini-
cal trials and the research team [31].
The results of clinical trials are not always published; 
in such cases, the lack of publication of certain results 
requires clarification. The public expects researchers to 
provide reliable information on the results of clinical tri-
als [32]. The results of clinical trials published in scien-
tific journals do not usually reach the wider public, and 
are rarely advertised in the press available to laymen.
The public wants to have access to the results of 
clinical trials: patients wish to know their results to make 
decisions about continuing treatment, interpreting emerg-
ing side effects or deciding about seeking alternative 
treatment. The language of information adapted to the 
knowledge of lay people consists in verbal and symbolic 
messages: what to say and how, to whom and in what 
form, so as not to induce negative emotions and bad re-
actions. The information provided to the public should 
discuss positive and negative results, prevent selective 
publication of results, especially taking into account the 
consequences that publishing these results would have 
for the people actively using the results of these studies 
(i.e. patients).
The role of the media in providing information on clinical trials
The interest of the media and decision-makers associ-
ated with treatment policy should play an important role 
in disseminating research results through modern infor-
mation channels. Their popularization should take place 
via the Internet, social media: e-mails, blogs, Twitter, 
social networks, including patient organizations.
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Figure 2. Factors creating a network of trust in clinical trial results.
Source: Own study.
1. Clinical trials are dangerous. • Ill people receive a medicine that has been previously tested – while the new 
drug is researched, they are under medical supervision.
2.  Pharmaceutical companies do what they like, no one 
controls them.
• Nonsense – the need to fulfil formalities – obtaining the consent of the 
bioethical commission.
3. Doctors use patients and put their health at risk. • Incorrect – the patient may start clinical trials only after giving written con-
sent, and after receiving information about all adverse reactions connected 
with the study. They can withdraw from the study at any time.
4. Patients earn money on clinical trials. • Healthy volunteers YES; patients receive medical care and free medicines.
Table I. An example of a media message by “Super Express”.
Source: http://www.se.pl/wiadomosci/polska/obalamy-mity-o-badaniach-klinicznych_426085.html (accessed: 20.11.2018) [33]. 
An example of a media message about clinical trials 
is that prepared by “Super Express”. However, it should 
be emphasized that this message does not remove all 
doubts (Table I).
Summary
The rules regulating the inclusion of various groups 
of patients or healthy people in clinical trials depend on 
social attitudes towards research in medicine, but also on 
the attitudes of the social environment (network of social 
relations) assessing the way of recruiting for research or 
participation in research from the perspective of groups 
represented in studies and social groups not participating 
in them.
Social attitudes are based on evaluating the objective 
benefits of participating in research, but the subjective 
norms and attitudes of family and friends towards clinical 
trials also play an important role. The significance attrib-
uted to medical research has an important impact on the 
participation of healthy volunteers in such studies, and is 
associated with many ethical questions.
Inequalities in approaching different groups of pa-
tients include considering the question whether it is worth 
carrying out research in a small number of patients suf-
fering from a disease that is to be the subject of clinical 
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trials, especially if this group of patients requires costly 
therapies, or the opposite situation – too many patients 
included in the clinical trial.
Debating clinical trials with the public should be treat-
ed as part of the clinical trial project, on an equal footing 
as legislative activities and the registration of clinical tri-
al results. References to such authorities as the Cochrane 
Collaboration Group or medical professionals, can be 
reinforced by providing medical information not only in 
medical journals, but also through social networks, and 
the promotion of clinical trials on the Internet. Changes 
in social attitudes may be expected to occur through the 
dissemination of knowledge about the real role of clinical 
trials in the modern world, counteracting the ‘culture of 
distrust’ towards clinical trials, gradual building of so-
cial trust in clinical trials, ‘attracting’ patients to research 
rather than ‘pushing them away’, increasing the capacity 
to understand messages about various aspects of clinical 
trials, appreciating the role of patients as co-authors of 
clinical trial results, and the role of mass media in the 
objective dissemination of clinical trial results.
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